Ongentys FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
Ongentys (opicapone) is a catechol-O-methyltransferase (COMT) inhibitor indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.
Development timeline for Ongentys
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.